- cafead Mar 23, 2023 at 11:42: AM
via AbbVie’s Skyrizi, which is already making inroads in Crohn’s disease, has clinched a win in another inflammatory bowel disease (IBD).
Skyrizi as an induction therapy helped significantly more patients with moderate to severe ulcerative colitis achieve clinical remission compared with placebo in a phase 3 trial, AbbVie said Thursday.
article source
Skyrizi as an induction therapy helped significantly more patients with moderate to severe ulcerative colitis achieve clinical remission compared with placebo in a phase 3 trial, AbbVie said Thursday.
article source